(Q46622243)

23 December 2017

title

Treatment of chronic hepatitis C infection: one step at a time (English)

1 reference

23 December 2017

1 reference

Gary L Davis

1

1 reference

23 December 2017

Karen L Lindsay

series ordinal

2

1 reference

23 December 2017

publication date

1 August 2005

1 reference

23 December 2017

Lancet Infectious Diseases

published in

1 reference

23 December 2017

volume

5

1 reference

23 December 2017

issue

8

1 reference

23 December 2017

page(s)

524-526

1 reference

23 December 2017

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Hepatitis C: and miles to go before we sleep

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Non-A, non-B posttransfusion hepatitis--a decade later

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Interferon alpha in hepatitis type B and non-A, non-B. Defective production by peripheral blood mononuclear cells in chronic infection and development of serum interferon in acute disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Pilot study of recombinant human alpha-interferon for chronic type B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Alpha interferon treatment of chronic non-A, non-B hepatitis caused by intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970193-6

7 January 2021

10.1016/S1473-3099(05)70193-6

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017